Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

HIV Protein Strikes a Fleeting Pose

Published: Friday, August 03, 2012
Last Updated: Friday, August 03, 2012
Bookmark and Share
New intermediate structure of HIV entry protein offer a potential target for developing an HIV vaccine.

NIH scientists have discovered a new intermediate structure of the HIV entry protein. This temporary structure, which occurs just before HIV infects a cell, may offer a potential target for developing an HIV vaccine.

Scientists determined the structure of the HIV envelope glycoprotein in its activated state, in which 3 helices (center) spring out at the center of the molecule. Image courtesy of Dr. Sriram Subramaniam, NCI.

HIV, the virus that causes AIDS, affects more than 30 million people worldwide, and millions more become infected each year.

Once in the body, HIV invades immune cells known as T cells by latching onto a receptor and a co-receptor on the cell's surface. T cells are responsible for fighting off viruses-including HIV itself.

Despite recent advances in treatment, scientists have not yet designed a vaccine that protects people from HIV.

One challenge is that the proteins on the viral surface-the HIV envelope glycoproteins (Env)-mutate rapidly, changing their shape and evading the immune system.

Only the deep inner portions of Env remain constant, and these are generally hidden from the immune system by the glycoprotein's structure.

Over the last 25 years, scientists have visualized the structure of Env and uncovered details of the HIV entry mechanism. But much less is known about the steps between Env binding to the T-cell receptor known as CD4 and the point at which the virus fuses with the cell.

In a study published in PLoS Pathogens on July 12, 2012, a team of scientists led by Dr. Sriram Subramaniam of NIH's National Cancer Institute (NCI) set out to investigate the structural changes of Env during this early stage of HIV infection.

The researchers used a technique called cryo-electron microscopy to visualize the native structure of Env. In this technique, the whole virus or purified viral proteins are frozen so rapidly that the ice stays liquid-like.

This specialized frozen state keeps the proteins in their natural, life-like positions as they're imaged under the electron microscope, which can reveal the structure of molecules at high resolution.

The researchers first obtained a 3-D structure of Env alone. They then compared that structure with the glycoprotein bound either to the CD4 receptor or to an antibody that mimics the co-receptor.

The structures revealed that when Env is bound by either of the receptors, the glycoprotein opens up into an activated state, in which 3 helices spring out at the center of Env.

This novel activated intermediate lies midway between the inactive (unbound) position and the next known structure of Env, which occurs just after fusion. The finding offers a look at one of the first steps in the HIV fusion process.

The scientists also determined the structure of Env bound to a neutralizing antibody, VRC01, which is known to block many strains of HIV from infecting human cells. This antibody, the researchers found, keeps Env in its inactive state and prevents the glycoprotein from binding to its receptors.

“We now have an improved understanding of how different neutralizing antibodies work,” says Subramaniam. “What we also have is a unique snapshot of the surface of HIV just as it is about to infect a cell. We anticipate finding more of these intermediates as we continue our work, and each will likely provide invaluable information for designing effective HIV immunogens and vaccines.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
NIH Awards Grants to Explore Vaccine Adjuvants
NIH awards six grants to explore how combination adjuvants improve vaccines.
Wednesday, April 06, 2016
Experimental Vaccine Protects Against Dengue Virus
An experimental dengue vaccine protected all the volunteers who received it from infection with a live dengue virus.
Wednesday, March 30, 2016
Promising Experimental Dengue Vaccine
A clinical trial in which volunteers were infected with dengue virus six months after receiving either an experimental dengue vaccine or a placebo injection yielded starkly contrasting results.
Thursday, March 17, 2016
Experimental Ebola Antibody Protects Monkeys
Antibody isolated from Ebola survivor can advance to clinical trials.
Friday, February 26, 2016
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Friday, February 05, 2016
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Friday, January 15, 2016
NIH Unveils FY2016–2020 Strategic Plan
Detailed plan sets course for advancing scientific discoveries and human health.
Thursday, December 17, 2015
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Tuesday, November 10, 2015
NIH Announces High-Risk, High-Reward Research Awardees
NIH to fund 78 awards to support highly innovative biomedical research.
Wednesday, October 07, 2015
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Thursday, August 27, 2015
Large Percentage of Youth with HIV May Lack Immunity to Measles, Mumps, Rubella
NIH study finds those vaccinated before starting modern HIV therapy may be at risk.
Tuesday, August 18, 2015
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!